Metformin (glycinate)

• UNSPSC Description:

  Metformin glycinate inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin glycinate can cross the blood-brain barrier and triggers autophagy[1].

• Target Antigen:

  AMPK; Autophagy; Mitophagy

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Epigenetics;PI3K/Akt/mTOR

• Field of Research:

  Cancer; Metabolic Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/metformin-glycinate.html

• Smiles:

  O=C(CN)O.N=C(NC(N(C)C)=N)N

• Molecular Weight:

  204.23

• References & Citations:

  [1]Soraya H, et al. Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacol Rep. 2012;64(6):1476-84.|[2]Quaile MP, et al. Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol. 2010 Mar 15;243(3):340-7.|[3]Xue J, et al. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis. Reproduction. 2013 Aug 21;146(4):397-406.|[4]Otto M, et al. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes Metab. 2003 May;5(3):189-94.|[5]Avci CB, et al. Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev. 2013;14(2):765-8.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 4

• CAS Number:

  121369-64-0